Abstract
This study describes the real-world prescribing patterns, effectiveness, and tolerability of cabozantinib in patients in Taiwan with advanced renal cell carcinoma (aRCC) that progressed despite prior antiangiogenic therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have